Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of “Buy” from Brokerages

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been assigned a consensus recommendation of “Buy” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. Eleven analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have issued a report on the stock in the last year is $64.44.

Several research firms recently issued reports on JSPR. HC Wainwright decreased their target price on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. UBS Group began coverage on shares of Jasper Therapeutics in a research report on Thursday, February 13th. They issued a “buy” rating and a $38.00 target price on the stock. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price on the stock. Royal Bank of Canada decreased their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research report on Thursday, January 9th. Finally, JMP Securities reissued a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday, January 6th.

Jasper Therapeutics Price Performance

Jasper Therapeutics stock opened at $6.25 on Thursday. The firm’s 50-day moving average is $11.81 and its two-hundred day moving average is $17.28. Jasper Therapeutics has a 12-month low of $4.55 and a 12-month high of $31.01. The stock has a market capitalization of $93.75 million, a P/E ratio of -1.32 and a beta of 2.11.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its stake in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after purchasing an additional 1,698 shares during the period. MetLife Investment Management LLC raised its stake in shares of Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,873 shares during the period. Wells Fargo & Company MN raised its stake in shares of Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after purchasing an additional 3,828 shares during the period. EntryPoint Capital LLC purchased a new stake in shares of Jasper Therapeutics during the fourth quarter valued at approximately $223,000. Finally, Jane Street Group LLC purchased a new stake in shares of Jasper Therapeutics during the third quarter valued at approximately $251,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.